Filed Pursuant to Rule 433

Issuer Free Writing Prospectus

Dated March 1, 2024

(To Preliminary Prospectus dated February 29, 2024)

Registration Statement No. 333-276124

NEONC TECHNOLOGIES HOLDINGS, INC.

This free writing prospectus relates only to the initial public offering of shares of common stock of NeOnc Technologies Holdings, Inc. (the “Company”) and should be read together with the preliminary prospectus dated February 29, 2024 (the “Preliminary Prospectus”) included in Amendment No. 4 to the Registration Statement (“Amendment No. 4”) on Form S-1 (File No. 333-276124) relating to the offering of such securities. Amendment No. 4 may be accessed through the following link:

https://www.sec.gov/Archives/edgar/data/1979414/000182912624001215/neonctechnologies_s1a4.htm

NeOnc Technologies Holdings, Inc. (the “Company”) has filed a registration statement (including a preliminary prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the Company has filed with the SEC for more complete information about the Company and this offering. You may get these documents for free by visiting EDGAR on the SEC web site at www.sec.gov. Alternatively, the Company, any underwriter or any dealer participating in the offering will arrange to send you a copy of the Preliminary Prospectus if you request it from: Loop Capital Markets LLC, Attn.: Sidney Dillard, 111 West Jackson Blvd., Suite 1901, Chicago, Illinois 60604, by telephone at (312) 356-5008 or by email at sidney.dillard@loopcapital.com. U.S. residents only.

M a r c h 2024 R e m o v i n g B a rr i e r s t o E ff e c t i v e N e u r o - D r u g D e li v e r y Fi l ed P ur s ua n t t o Rule 433 R e g i s t r a t i on N o. 33 3 - 276 1 24 Re la t i n g t o P r el i m i n ar y P r os p ec t us Da t ed 2/29 / 2 0 24 I ss u er F r e e W r i t i n g P r o s p e c t u s

Importa n t C a u tio n s Re g a r di n g For w a r d Loo ki n g Sta teme n ts Thi s doc ume nt doe s not c ons t i t u t e or f o r m part of a n inv i t at ion or r e c o m me n da t ion t o s ub s c ri b e f o r or pur c has e an y s e c uritie s . The dis t ri b u t ion ma y be r e s t ri c t e d by law in c e rtain juri s di c t ions and p e r s ons in t o w hos e pos s e ss ion t his doc ume nt c o m e s s hould inform t hemse lv e s a b o u t , a nd o bs e r v e , a ny s uc h r e s t ri c t i o n. A ny f a ilure t o c o m ply w i t h t h e s e r e s t ri c t ions ma y c ons t i t u t e a v iol a t ion of t he law s of an y s uc h juri s di c t ion. N e O nc T ec hnolo g ie s H oldin g s , Inc . ( “N e O nc ”, “ C o m pany,” “our” or “ours ”) s hall not hav e any r e s pons ibility f o r an y s uc h v iol a t ions . A ny d e c is ion t o pur c has e or s ub s c ri b e f o r s e c uritie s in an y o ffe rin g mu s t be ma de s ole ly on t he bas is of t he infor m at ion is s u e d in c onne c t ion w i t h s uc h o ffering . Thi s doc ume nt w a s pr e par e d e x c lus iv e ly f o r t he b e n e fit an d in t e rnal us e of inv e s t ors t o e v alua t e t he fe a s ibility of a pos s ible t ran s a c t ion or t ran s a c t ions an d doe s not c arr y an y rig ht of pub li c at ion or dis c los ure t o an y o t h e r party. Thi s doc ume nt is in c o m pl e t e w i t hout r e fe r e nc e t o an d s hould be v ie w e d s ole ly in c onjun c t ion w i t h, t he oral br ie fing pr ov id e d by t he C o m pany. Thi s pr e s e n t at ion ma y not be us e d f o r a ny o t her purpo s e w i th o ut t he prior writ t e n c o ns e nt o f t he C o m pany. In pr e paring t his doc ume n t , w e hav e r e lie d upon and a s s ume d, w i t hout ind e p e nd e nt v e rifi c at ion, t he a c c urac y and c o m pl e t e n e ss of al l infor m at ion a v aila ble from pub lic s our c e s or w hic h w a s pr ov id e d t o us or o t h er w ise r e v ie w e d by us . We do not r e pr e s e nt t hat s uc h infor m at ion is a c c ura t e or c o m pl e t e , an d it s hould not be r e lie d on a s s uc h. A ny opinions e x pr e ss e d h e r e in r e f l e c t o ur jud g m e nt a t t his d a t e , a ll o f w hic h a r e a cc o rdin g ly s ubje c t t o c han g e . We hav e bas e d t he f o r w ar d - lo o k ing s t at e me n t s on our c urr e nt e x p e c t at ions an d pr oje c t ions abou t fu ture e v e n t s . Th e s e f o r w ar d - lo o k ing s t at e me n t s ar e s ubj e c t t o k now n an d unk now n ri s k s , un c e rta in t ie s , an d a s s ump tions abou t us an d our affili a t e c o m pani e s w i t h r e s p e c t t o s p e c ific f a c t ors id e n t ifie d in t his pr e s e n t at ion an d t he C o m pany’s filin g s w i t h t he U .S . S e c uritie s E x c han g e C o m mis sion, an d w hic h ma y c au s e our a c t ual r e s ul t s , le v els of a c t iv i t y, p e rforma nc e or a c hie v e me n t s e x pr e ss e d or implie d by s uc h f o r w a r d - l o o k ing s t a t e m e n t s di f fer m a t e ria lly fr o m t h o s e c urre n t ly ant i c ipa t e d in s uc h s t at e me n t s . Thi s pr e s e n t at ion has b e e n pr e par e d by t he C o m pany f o r infor m ational p urp os e s only an d not f o r an y o t h e r pur pos e . This pr e s e n t at ion s hall not c ons t i t u t e a n o ffe r t o s e ll or t he s olic i t at ion of a n o ffe r t o buy , nor s hall t h e r e be an y s al e of s e c uritie s in any jurisdic t i o n in w hic h s uc h o f f e r, s o lic i t a t i o n o r s a le w o uld be unlaw ful pr ior t o t he r e g is t ration or qualific at ion und e r t he s e c uritie s law s of an y s uc h juri s di c t ion. THI S P R E S E N T A TI O N A N D A N Y O THE R IN F O R MA TI O N TH A T MA Y BE FU R N IS H ED BY U S IN C L U D E S O R MA Y IN C L U D E C E R T A IN S T A TEME N T S , E S TIM A TES A N D F O R W A R D - LO O KIN G P R O J E C TIO N S O F TH E C O MP A N Y WITH R E S PE C T TO TH E A N TIC IPA TE D FU TU RE P E R F O R MA N C E OF TH E C OMPA N Y . S U C H S TA TE M E N T S , ES TIM A TE S A N D F O R W A R D - LO O KIN G P R O J E C TI O N S R EFLE C T V A R IOUS A SS U MPTIO N S O F MA N A G EMEN T TH A T MA Y O R MA Y N O T P R O V E TO BE C O RR E C T A N D IN V O L V E V A R IOUS R IS KS A N D U N C E R T A IN TIES. Th e C o m pany has file d a r e g is t ration s t at e me n t on For m S - 1 ( R e g is t ration N o. 3 3 3 - 2761 2 4 ) w i t h t he S e c uritie s an d E x c han g e C o mm is s i o n ( t he “ C o mm is s i o n”) f o r t he o f f e ring t o w hic h t his pr e s e n t at ion r e la t e s . B e f o r e you inv e s t , you s hould r e a d t he r e g is t ration s t at e me n t an d o t h e r doc ume n t s t hat w e hav e file d w i t h t he C o m mis s ion f o r mo r e c o m pl e t e infor m at ion abou t us an d t he o ffering . Y ou ma y g e t t h e s e doc ume n t s f o r fre e by v is i t ing EDG A R on t he C o m mis s ion’s w e bs i t e at www .s e c . g ov . F r ee Writin g Prosp e ctus St a teme n t Thi s pr e s e n t at ion has b e e n pr e par e d by t he C o m pany f o r infor m ational p urp os e s only and not f o r an y o t h e r pur pos e . Thi s pr e s e n t at ion is not a pr os p e c t us an d is not a n o ffe r t o s e ll, nor a s olic i t at ion of a n o ffe r t o buy , s e c uritie s . Th e C o m pany has file d a r e g is t ration s t at e me n t on For m S - 1 ( in c luding a pr e liminary pr os p e c t us ) ( R e g is t ration File N o. 33 3 - 276124 ) w i t h t he S e c uritie s an d E x c han g e C o m mis s ion ( t he “S E C ”) f o r t he o ffe ring t o w hi c h t his pr e s e n t at ion r e la t e s . Th e r e g is t ration s t a t e m e nt h a s n o t ye t be c o m e e f f e c t iv e . Th e C o m pany's s e c uritie s ma y not be s old, nor ma y o ffe r s t o buy t he C o m pany's s e c uritie s be a c c e pte d, prior t o t he t ime t he r e g is t ration s t at e me n t b e c o m e s e f f e c t iv e . © N e O n c T e chn o l o g ie s H o ldings , I nc. 202 2 - 2024 . A ll R ig ht s R e se r v e d. P r o p r ie t a r y & C onfid e nt i a l. P r o d u ct o f C M A . 02292 4 2 B e f o r e you inv e s t , you s hould r e a d t he pre li m in a r y prospe c t us a nd t he o t her doc ume n t s t hat t he C o m pany file s w i t h t he S E C f o r mo r e c o m pl e t e infor m at ion abou t t he C o m pany an d t his o ffering . Y ou ma y ob t ai n t h e s e doc ume n t s f o r fre e by v is i t ing t he S E C w e bs i t e a t www . s e c . g ov . A l t e rna t iv ely, c o pie s o f t h e prospe c t us m a y be ob t ain e d from t he Book R unning Mana g e r of t he IPO lis t e d on t he f o llow ing s lid e .

Initia l Pu b li c Of f ering Summary 3 N eO n c T e c h n olog ie s H o l d i ng s, I n c. I s s u e r N as d a q G l o b a l M a r k et: N THI Pr opose d E x ch a n ge & Ticke r 6,00 0 , 00 0 Sh a res of Common St ock Tr a n s a c tion S ize 15% O v e r - A llotme n t O p tion $11 .2 5 - $13 . 75 Pr ic e Per S h a re $75 mi l l i on ( b as ed on th e m i d p oi n t of p rice p er s ha re) Of f erin g A mou n t L o op Ca p i t a l Mar k e t s S ol e Book R unn i n g M a n ag e r Ma x im Gro u p LLC B r oo kli n e C ap i t a l M a r k ets Co - M a n ag ers 1 6 ,5 60 , 00 0 Sh ar es C ommo n S toc k C u r r e n tly O u tsta n d i n g • C l i n ical T r i a ls • R e se a r c h & Developm e n t • Bri dg e N o t e • Ge n er a l Cor p or a t e P u r p oses & Wo r k i n g Ca p i t al • Finan c ial A d v isor F e e • Se tt le me nt Payment • Lic e nse A g r ee m ent F ees • Acc ru e d S alari e s U s e o f Pr oc e e ds

Int r odu c tion Ne O n c i s a c l i n i ca l sta ge l i fe sciences c o mpa n y . F oc us e d on d e v e l o pm e nt & c o m m e r c i a l i z at i on of c e nt r al ne r v ou s sys tem ( C N S ) the r ap e uti c s. I P p o rtf o l i o p r o tecte d b y pat ents e x tend i n g t o 2031 – 2038. I nc l ud e s c o n j ugates & f o r m u l at i on s wi th F D A - ap p r o v e d d r ugs. Mult i - bil li o n - d o l la r , h i gh - g ro wth add r es s ab l e ma r k ets. G r e a t unm e t ne e d su p p o r ts c o m m e r c i a l l aun c h. P h a s e I & I I First t h r ee t h e r apeut ic s i n P ha se I & II cl i n i ca l tr i a l s f or ma l igna n t gl i o b l a sto m a s ( GBM ) and M e n i ng i om a s . Ad v an c i ng un d e r F D A F ast - T r ac k & I nv e stig a tio n a l N e w Drug sta t us . Our pl atf o r m technolog y ha s p r o duced a p o rtf o l i o o f n o v el drug cand i dat es & d e l i v ery methods. Des i gne d to ad d r e ss the p e r s isten t c h al l e n ge i n o v e r c o m i ng the blo o d - b r a i n barrier ( BB B ) . S e ve r al pu b l i sh e d studies i nd i cat e the i r po tential v i ab i li ty a s a d e li v e r y v e h i cl e f or ch e m o - the r ap e uti c s an d ab i li ty to e f f e ct b r ai n ca n c e r t r e at m e nt. 4

Use o f P r oceed s Al l ocat i on $75M 40% P l u s 15% G r eensh o e 5 Gene r al C o rp o r a t e P urpo ses & W o rk i n g C ap i t a l $29.9M Re sea rc h & De v elopm e nt $1 1.4M C l i n c i a l T ri a ls $2 3.7M B ridg e N o te $10.0M 15% 32% 13%

The Need 1 Million Ameri can s Li v i ng with a P r i ma r y B r ai n T um or 13,657 a r e Ch i l d r e n 94,390 N e w P r i ma r y B r ai n T umo r s Diagno se d T h i s Y e ar 3,920 i n Ch i l d r e n #1 B r ai n T umor s a r e t he L e ad i ng Caus e Of Can c e r - Re l at e d Death Amo ng Ch i l d r e n 18,990 P at i e nts Ex p e ct e d to L o se T h e i r L i fe Due t o Ma l i gn a nt B r ai n T umo r s T h i s Y e ar 1 - in - 143 Y ou r Odds of D e v e l o p i ng B r ain Can c e r i f Y ou ’ r e Ma l e 1 - i n - 188 i f F e ma l e 28% of B r ai n T umor s a r e Ma l i gn a nt ( Can c e r ou s ) So u r c e : N a t i on a l B r a i n T u mor So c i e t y e s t i ma t e d f i g u r e s a s of N ov. 2023 . C h il d r e n = A g e s 0 - 14 6

The Cha l lenge Wh i l e the F D A has a p pr o v e d m a n y d r u gs f or t r e ati n g M a l i gn a n t Gl i o b l a s to m a s ( GB M ) , surv iv al r a t es r ema i n l o w wit h no si gn ifi c a n t i m p r o v em en t i n p r ognosi s o v er pa s t 50 y e a rs. T h e r a p e u t i c s c a nn o t e n t e r C e n t r a l N e r v o u s S y s t e m ( C N S ) du e t o b l oo d - b r a i n b a rr i e r ( BB B ) . N a t u r a l b r a i n r e s p o n s e s c oun t e r a c t t u m o r - t a r g e t i n g m e d i c a t i o n s . Meta b oli c c a sc a d e s in GB Ms p r ev e n t e f f e c t i ve t r e a t m e n t s t h r ou g h : • O pt i m i z a t i o n of g l uco s e us e . • A l t e r n at ive nutr i e nt pre c u r s o r s for e n e rgy pro d u c t i on. • I nd u c t i o n o f h y p o x i a to e n h anc e t u mo r g ro w t h . H e t e r o g e n e i t y o f G B M s c on t r i bu t e s t o t h e r a p e u t i c r e s i s t a n c e b y p r e v e n t i n g a d e qu a t e c on t r ol o f t h e e n t i r e t u m o r m a s s b y a s i n g le d r u g . S te m c el l - lik e ch a r a c t e ri s ti c s o f GB Ms h ave r e sis t a n ce t o c u rr e n t s t a n d a r d t r e a t m e n t o p t io n s: 8 Mont h s M e d i a n Sur v i v a l Ra te, Makin g GBM Amo ng the M o s t Letha l of B r ai n Can c e r s . 1 13, 4 00 or 14 .2 % of N e wl y Diagno se d B r ai n T umo r s this Y e a r wi ll be Mali gna nt G l io b l a sto mas (GBM). 1 o u r c e: C h a llen ges i n t h e T r ea t m en t o f G li o b l a s t o m a : Mu l t i syst em M e c h a n is m s o f T he r a p eu t i c Res i s t a n c e , A u g. 2018 1 ) N a t i on a l B r a i n T u mor So c i e t y e s t i ma t e s a s of N ov. 2023 . 1 0 ,000 S t ill Die fr om GBM Ev e r y ye ar Des p i te Ad v an c e d Su r ger i e s, Ra d i at i on T r e at m e nts, and N e w Ch e m othe r ap i e s . 2 2 ) B r a i n t u me r . or g. 202 3 e s t i ma t e s . 7 U p r e gu l a t i o n o f E ff lu x T ra nsp o rt e r s C he m o t he r ap y P r o m o t i o n o f G li o b l as t o m a S t e m C el l P r o li fe r a t i o n I n N eu ro g e ni c Z o ne s R ad i a t i o n I mm un e Supp r e ss i o n S Imm uno t he r ap y

Our So l u tio n : NE O 1 0 0 ▪ N E O 100 , our fi r s t d ru g c an d i d at e , r e p r ese n ts the f o u n d at i on of our N E O platf o r m f o r d e v e lo p i n g n o v e l drug s & d e l i very m e tho d s tha t a d d r ess th e s e cha l l e ng es . ▪ N EO10 0 is a n o ve l paten ted c o m p o s itio n o f matt e r p r o d u c ed b y our p r o p ri e tar y synthes i s of P eri ll yl A l c o h o l (POH ). ▪ P OH i s a n a tu rall y oc c u r r i n g s u bstan c e f o u n d in the es s e n ti a l oils of va riou s p la nts, s uch a s citru s a n d p e p perm i n t . F D A - ap p r o ve d a s a f oo d f lav o rin g age n t. ▪ O u r p r opri e tar y , p at e nt e d te chnolog y i n vol v e s the d eri va ti zation of PO H w it h a c r y s tal l i ne i n te rme d ia te . T h i s e n a b l e s the p r od u ctio n of ult r a - p u r e, p h a r maceuti c a l - g r a de N E O10 0 . O u r p a t ent e d N EO 100 i s Des i g n ed t o En a b l e t h e De l i ve r y o f T h e r a p euti c s t o t h e B r a i n f o r t h e T re a t m e n t o f C N S - b a se d D i seases . NE O100 – Our p r o p r i e t a r y syn thesi s of P e r i l l yl Al c oh ol ( P OH ) 8

NEO100 i s Designe d t o Enab l e S e ve r al Potentia l l y Benef i ci a l Appl i cat i on s & Actio n s 1 Act as a r egula tor fo r neu r o l og i c pa t hwa y s ass o cia t e d wi th tumo r c e ll g r o wth. When deli v e r ed i n tr an asa l l y , i ts sm al l m o l e c u l a r si ze sh ou l d al l o w i t to b ypas s the Bl o o d B r ai n Bar r i e r ( BB B ). When deli v e r ed i n tr a - art eria l l y , i t ma y c r e at e a tem p o r ar y o p e n i ng i n the BB B , al l o wi n g l a r ger m o l e c u l e the r ap e uti c s to pas s t h r ough. In h i gh c o ncent r a t ions ma y ac t a s a the r ap e utic fo r b r ai n canc e r s . In l o w c o ncent r a t ions to ac t a s so l v e nt f or t r ad i tio nal la r ge mo l ec u l e t he r apeuti c s, wh i c h sh ou l d e nab l e them to b ypas s the BB B . C o n j uga t e wit h o t h er C NS t h e r apeut ic s t o c r e at e c o m p ou nd f o r m u l at i on s that ma y be ca p ab l e of BBB pene t r at i on & g r e at e r the r ap e utic e f f e ct. + 1 ) B ase d o n a ni m a l m o de ls. 9

Na / K - A T P ase In h i bit ion E ndo pl a smi c Re t i cul u m S tr ess ( Unf o l d ed P r o t e in Re s p o n se) C ell C y cl e Ar r est Apopt o sis ( C e ll Death) RA S Onc o p r o te i n In h i bit ion E lect r o l y t e Im ba l an c e ( Na + , K + , Ca ++ ) NE O 1 0 0 Potential M e ch a n i s m o f Act i on N E O 100 1 3 2 C y topl a smic M e mb r an e D isrupt i o n 10

Wh a t i s th e B l oo d B r ain Ba rrier? Blo o d - B r ain Ba r ri e r (B B B) is a s e m i p erm ea b le bar r ie r o f e n d o th e l i a l c e l ls. Con t r ols h o w so l u bl e s u bstan ce s ci r cul a ti ng in the b lood s t r ea m c r o s s i n to the ce n t r a l n e rvous s y s te m (C N S). H i g h l y se l ect ive & i nt r i c a t e : ▪ A l l o ws o x y gen an d n u tri e n t mol ecule s to p as s th rough to t h e b r a i n. ▪ B u t p r e v e n t s p a ss a ge o f p o t e n t i a l l y h a r mf u l mol ecule s , s uch a s p at h oge n s an d hy d r op h i l ic (w at e r - s olu b l e ) mol e cul e s tha t c o u l d ca r ry d isease. H o w ev e r , th e BB B a lso c r eates a b a rr i e r to d e l i v eri ng p oten ti a l ly l i fesav i ng th e r a pe u ti c s . 11

N a sal C a v i t y O l fac t ory N e r ve Bl oo d B r a i n B a rr i er (BB B ) B r a i n T u mor I n t r an asal D el i very ▪ Our i n tr an asa l ( no se ) d e li v e r y m e thod i s d e si gne d to al l o w d r ugs to b ypas s the BBB an d enter the b r ain th r ou gh the o lf a cto r y o r tr i gemina l nerve s . ▪ Int r ana sal d r u g d e l i very i s n o n - in v asi v e: Can be e as i l y ad m i n i s te r e d b y or f or t he pati e nt, an d the r e b y ca n p o tentia l l y r e du c e t r e at m e nt c o st s an d i m p r o v e t r e at m e nt e f f i cac y . ▪ Int r anasa l de li v e r y ca n als o po t ential ly enab l e r apid o nse t o f act io n an d av o i dan c e of f i r s t - pa s s m e t a b o li s m e f f i cac y d e c r e as e . Microe m u lsion Droplets C on ta i n i n g Dru g Mol e c u l e s A N o s e Mask & N ebuli zer A r e U sed f o r In tr an asa l D eli v ery o f T h e r apeut ics S m a ll mol e c u l e t h e r a p euti c s a e r o s o l s a r e c r ea t e d t o pas s t h r o u gh t h e o lfa c t o ry mu c o sa to C N S c o nn ec t e d n erve t i s s u e. O n c e i n t h e n e r ve p a t h w a y , suc h sma ll mo l e c u le t h e r a p e u t i cs m a y be p i c k ed u p b y t h e b r a i n ’ s C e r eb r o s p i n a l fl u i d (C SF ) , t h e r e b y b y pas si n g t h e BB B . T h e C SF sur r o un ds t h e b r a in t i s s u e, p o t e n t i a l l y a l lo win g s m a ll - mo l e c u le t he r ape u t i cs t o r eac h a t a r ge t ed d i seas e sit e , suc h a s a GB M t u mo r. N EO 1 00 i nt r anasal de l i ver y i s antic ipate d t o p r o v i d e O n co l ogy Ph ys i c i an s & C N S C h e m o - t h e r ape u t i c Man u fac t u r ers t he ve h i c l e t h e y ha v e long sough t t o i m p ac t t he ef f i ca c y of t h e i r t r eatmen t p r o t ocols. 12

NE O 2 1 2 – Our Fi r s t Dru g Bio c on j ugate NE O212 i s O u r First Drug C o n j uga t e & S ec o n d P r o duct C an dida te ▪ N o v el h ybrid c o mp ound , w i th NE O100 c ov al e nt l y c o n j ugated ( c o nn e ct e d) to T em o z o lomide ( T M Z ) , a n alky l at i ng age n t. ▪ F D A - ap p r o v e d T M Z i s c ons i d e r e d c u r r e nt standa r d of c h e m othe r ap e ut i c ca r e f or pati e nts wi th Gli o b l asto m a ( GBM ) . NE O 100 T e m ozolomid e (TMZ ) C a rb a mide B ond N E O2 12 B ioc o n j uga te d M o lecu l e P urpo se ▪ D esigned t o mo r e e f ficien t ly penet r a t e the BBB an d d e li v e r a “ d o u b le p u n c h ” again s t ma l i gn a nt b r ai n l esi on s . ▪ NE O212 o f f ers an i n tr i guin g f eatu r e: a bi oc on j ug a t ed N E O 10 0 - T M Z c o u l d hav e a g r e at e r the r ap e utic i m p ac t than a si m p l e m i x of NE O 100 wi th T M Z. S t a t u s ▪ NE O 212 has c o m p l e ted p r e c l i n i c a l testi ng wi th i nv e sti g at i o nal n e w d r ug ( I N D ) ap p li c a tio n ap p r o v e d b y F D A. ▪ N o w with IND app r o va l , c l i n i c a l t r i al s ca n be gin with pr i mar y an d se c ond ary ma l i gn a nt b r ai n ca n c e r type s, testi ng b o th o r a l & i nt r anasa l d e li v e r y . 13

NE O 2 1 2 Theo r etical Mech a n i s m o f Acti o n PH>7 + H 2 O Al c o h ol Dehyd r og enase M TIC 5 - (3 - M e t hyl - 1 - t r ia ze n o )imida z o le - 4 - c a r b o x a m ide AIC 5 - aminoi midazo l e - 4 - car boxami d e (A I C ) M e t h y ld i a zo n i u m Ion + DNA Met h y l a tion Ap o pt o sis (T umor C e ll D e ath) E n do p l a smic R e ti cu l u m ( ER ) Str e ss PA P AL D N E O 212 C a r b a mi d e Bond N EO 100 T e m o zo l om id e ( TMZ) NE O212 : N o v e l hyb r i d c o m p ou nd , wi th 14 NE O100 b ond e d to T em o z o lomide ( T M Z ) , a n F D A - ap p r o v e d alky l at i ng age n t.

Our The r ape u ti c So l ut i o n s Add r ess H i gh G r o wth Gl o bal Mar k ets Gl o bal c e nt r a l ne r v ou s sys tem ( CNS) t r e at m e nt ma r ke t g r o wi ng a t 9.4% C A GR to $166 . 5 bil l i o n b y 2028. 1 Gl o bal b r ai n tumo r d r ug ma r ke t g r o wi ng a t C A GR of 9.0 % to $4 . 4 bil l i o n b y 2029 2 Major Mar k et D ri v ers ▪ I nc r e a s e d d i se as e i n c i d e n c e wi th agi n g p opu l at i on . ▪ G r o wing F D A ap p r o val fo r n o v e l t he r a p y and c o m b i natio n the ra p y . ▪ Ra d i at i on the ra p y ac c ou nts f or 38% of the b r ain ca n c e r t r e at m e nt m a r k e t, w i th d r u g t r e atm e n t s til l se c o nd m o stl y du e to c u r r e nt i ne f f i c i e n c i e s of d r ug d e li v e r y . 3 1) For t un e B u s i n e ss I n s i g h t s , J a nu a r y 202 2 2) For t un e B u s i n e ss I n s i g h t s D e c e m b e r 202 2 $8 9.0B 2 0 21 2 0 28 C NS T r eat ment Mar k et G l o ba l, U SD B illio n s 1 $166 .5B 9.4% C A G R $2 .4B $4 .4B 9 .0% C A GR 3 ) G r a nd V i e w R e s e a r c h R e por t 15 2 0 22 2 0 29 B r a i n T umo r Dru g Mar k et G l o ba l, U SD B illio n s 2

GB M T r eatm e n t Mar k et Opportun i ty M a lign a n t G li oblasto ma Mult i f o r m e (GBM) d ru g m ar k et e x p ec ted to g r o w a t 12 . 7 % C AGR to $2 .3B b y 2029 . 1 M a r k e t d r i v e n b y: ▪ Ri s i n g geri a tric p o p u l a ti o n . ▪ G r o wi n g i n c i d en c e c a s e s . ▪ S t r o n g p i p el i n e o f n e w p r o d u c ts . 1 G BM acc o un t s f o r mo r e tha n 50% o f a ll p r imar y m a li g n a nt br a i n tumo r s . 2 By c r ea ti n g a mo r e e f f e c ti v e d el i v er y mech a n i s m for G BM d ru g the r a p y , we b el i e v e we ca n signi f ic a nt l y imp a ct m a r k et dem a n d i n thi s sec t o r. 1 ) i H e a l t h c a r e A n a l y s t O c t ob e r 202 2 $0 .9B 2 0 21 2 0 29 GB M Dru g M ar k e t Outlo ok G l o ba l, U SD B illio n s 1 $2 .3B 12 .7% C A GR 2 ) B r a i n t u mo r . or g , 202 3 G li ob l a s t oma Fa c t s & Fi g u r e s 16

D e velopme n t & Cli n ic a l Pipelin e F D A Au t h ori z ed C li n i c a l T r i a l s Dr u g Ca ndid a t e A p p li c a t i on Indi c a t i on P r e c li n i c al I N D En a b li ng * Ph a s e I Ph a s e II Ph a s e III C omme r c i a li za t i on N EO 100 - 01 Int r a n a sal Re c ur r ent G r a d e I I I & G r a d e I V As t r oc y t oma B r a i n C a n c er w / IDH 1 M u t a t i on N EO 100 - 02 Int r a n a sal M en i n g i oma B r a i n T u mo r s N EO 212 O r a l Al l B r a i n T u mo r s N EO 100 - 03 P edi a t r i c A p p li c a t i on Int r a n a sal N EO 100 & C omb i n ed w i t h C he m ot h e r a p y Pedi a t r i c B r a i n T u mo r s * IN D Ena blin g : R e s e ar c h t o e s t abli s h w h e t h e r a c o m pound is r e a s onably s af e f o r ini t ial us e in hum a ns an d e x hibits pharmacol o g i c a l a c t iv i t y t hat jus t ifie s c o m me r c ial d e v e l op m e n t . O u r C li n i c a l P i p e li n e C o n t i n u e s t o E x p a n d t o I n c l u d e O t h e r A pp li c a t i o n s o f N E O 10 0 & N E O 21 2 Ph a s e 1 I N D F i led I m port a nt D is c lai m e r: Thi s d e v e lopmen t & c lini c a l pip e line is s ubj e c t t o r e g ula t ory appro v al , ri s k and un c e rta in t ie s , a s w e ll a s po t e n t ial c han g e s t o t he pip e line an d o t h e r f a c t ors t hat ar e b e yond our c on t rol. Ph a s e 2 Phase 2a 17

Our Expandin g I P Portf o li o o f G loba l Patents C r eates Competitiv e Barriers t o Entry N E O i s a Fi r s t - o f - i t s - k i n d P l at f o r m P r o tecte d B y P a t ents i n t h e U . S . , C an ad a , C h i na , U K & E U ▪ P a t en t s c o ver a g ent c om p os i t i o n & me t hods o f u se, i n c l u d i n g e n h a n c ed met h o ds d e signe d to d e l i ver ph a rm a - bas ed t h e r a p e u t i cs to t h e b r a i n . ▪ Pa t ents secu r ed un d er e x c l u s i ve g l ob a l li c ens i n g a g r ee m ent w i t h U SC. US C/N e O n c l i c e n s e is c o n sid e r ed US C' s la r ges t IP l ice n s e for c o mme r c ial i za t i o n o f c hem o t h e r a p i es r e l a t e d to b r a in & C N S d i se a ses . 1 ▪ Bi ot e c hn o l og y b re a kt h r o u g h s bas ed o n r esea r c h a n d d e ve l o p m e n t a t USC l e d b y N eO n c CE O , Dr. C h e n . ▪ P l a t f o r m t e c hn o l og y h a s p r oduc ed a n IP p or t f o li o o f n o vel d r u g c a n d i d a t e s , i n c l u d i n g c o n j u g a t e s a n d f o rmu l a t i o n s o f F D A - a p p r oved dr u gs , wi t h pate n ts e x t e n d i n g to 2 0 31 - 2038. U . S . P a t ents 28 Pate n ts Is sued 14 P aten t s P e n d i n g In tern a t i o na l P a t ents 6 5 Pate n ts Is sued 28 P aten t s P e n d i n g Comp o siti o n & M eth o d C l a ims Is sued & Pe n d i n g Pate n t A p p l i c a t i o n s N E O10 0 U ltr a p u r e POH – I ssue d p a t e n t s e xpiri n g in 203 1 : U . S . , Ca n a d a , U K , EU a n d C h i n a. POH C on j u ga t e s su c h a s T e m ozolomid e NE O 212 o r Rolip r a m NE O 214 – Is s u ed p a t e n t s e x p iri n g in 203 1 : U . S . , U K , EU a n d J a p a n . N E O40 0 POH c on j u ga t e d t o li n ole ic a c i d – A n t ic i p a t e d e x p ira t ion o f p e n d i n g a p p l i ca t io n s in 2031 U . S . , EU a n d C h i n a. N E O41 2 POH c on j u ga t e s with f a tt y a c i d a n d a c om po u n d su c h a s T e m ozolomid e / R olip r a m – I ssue d p a t e n t s e x p iri n g in 203 6 : U . S . , U K , EU, C h i n a , J a p a n a n d A u s t r a l i a . N E O21 8 POH c on j u ga t e d t o bro m op y ruv a te – I ssue d U . S . p a t e n t e x p iri n g in 203 7 ; A n t ic i p a t e same ex p i r a t i o n for p e n d i n g a p p li ca t i on s i n C h i n a, EU a n d J a p a n . N E O21 6 POH c on j u ga t e d t o Valp r o ic A c i d – A n t ic i p a t e e x p ira t ion o f p e n d i n g a p p l i ca t io n s in 203 8 : U . S . , EU , a n d C h i n a. 18 1 ) U SC a r t i c l e pu b li s h e d O c t . 19 , 2023 : U SC Li c e n s i n g A g r ee me n t R e a c h e d wi t h Fa c u l t y - l e d & Fou n d e d C omp a n y : U SC Li c e n s i n g A g r ee me n t C on s i d e r e d L a r g e s t I P Tr a n s f e r for C omm e r c i a li z a t i on of C h e mo t h e r a p i e s R e l a t e d t o B r a i n a nd C N S D i s e a s e

Pu b li s h ed stud y r esu l t s c o r r e l a t e d N E O1 0 0 wi t h im pr oved surv i va l vs. h ist o ric al c o n t r o ls Dem o n st r a t ed N E01 0 0 c o ul d b e c om e a v i a b l e t re a t m e n t for r ec u r r e n t GB M. NE O 1 0 0 Phase I Cl i n i ca l T ri a l Results In i t i a t ed : A pr i l 2 0 17 L en g t h : 2 y ea rs Si ze: 12 pa t i en t s L oc a t i o n s: C le ve l a n d C l i n ic; Un i versi t y o f W a s h i n gt o n /Seatt l e; U n i ve r s i t y o f Wisc o n si n ; a n d U n i vers i t y o f So u t h ern Ca l i for n ia P r ot oc ol • Pat i e n ts we re d i v i d ed i n to fo u r g r o u ps a n d give n va ry i n g d o s a ges o f N E O - 1 0 0 i n t r a n a s a l l y fo u r t i me s a day ( 3 8 4 mg , 5 7 6 mg , 7 6 8 mg , 1 1 52 mg) • Pat i e n ts sta y ed i n t h e tr i a l for a s l o n g a s t h e r e w a s n o d i se a s e p r og r ess i o n . Pa t i ent C r i t e r i a • C o n firmed p r og r ess i o n o r r ec u r r e n t g r a de IV Gl i o m a . • On a stab le s t e r o i d s d o s e f o r a t l east 5 d ays. • Fail ed p r e v i o u s r a d i a t i o n & T e m o zo l om id e t re a t m e n t . • 18 y ea r s o f a ge or o l d er. • EC OG p e r f o rm a n c e sta t u s o f 0 – 2. A l t ernat ive ly : • K a rn o fsk y ' s p e rf o rm a n c e sta t u s ≥ 6 0. • E x p e c t e d surv i va l r a te o f a t l e a s t 3 mo n t h s. • Sh o wed bas e l i n e MRI wi t h g a d o l i n i u m wi t h in two wee k s o f tr i a l. • Se i zu r es we re c o n t r o l l ed o n a sta b l e d o s e o f an t i - e p il e p t i cs f o r t wo we ek s pr i o r t o e n r o l l me n t. C o n c l u s io n s • 30 % o f pat i e n ts sh o wed n o d i sease p r og r ess i o n a ft e r 6 mo n t h s. • ~80% s u r v i val r a t e a fter 10 m o. wi t h pat i e n ts w h o r ece i ve d a m i n i m u m o f f i ve c y c l es. • C omp l e t e r e m i s s i o n o f d i se a s e a t 2 - y ea r m a rk wi t h o n e pat i e n t. • Pat i e n t who c o n t i nu ed to r ec e i ve N E O1 0 0 t r ea t m e n t sti ll a li ve a t 3 - ye a r m a r k . • The r a p y wel l t o l e r a t ed — o n l y m i n o r si d e effec ts ( i.e. , fa t i gue, h ea dac h es & r unn y n o se ). • O ve r a ll s u r v i val r a t e a n d s u r v i val t i me w i t h N EO 100 w a s s i g n i fi c a n t l y h i g h er vs. s im i lar GB M st u d i es o f t r a d i t i o n a l c hem o t h e r a p e u t i c dr u gs & d e l ivery met h o ds. S o u r c e : N e u r o - O n c o l o g y , S e pt e m be r 2020 : N E O 1 0 0 e n a ble s b r a in de li v e r y o f bl o o d - b r a in b a rr ie r impe r m e a ble t he r a pe ut ic s . 19

N E O100 Phase I Survival Da t a C h a r t s h o w s t h e s u r v i val r a t e o f a l l p a t ie n t s w i th in f i r st 24 m on t h s o f t h e t r i a l. S ho w s sp e cif i c h i g h l i g h t s o f s u r v i val a t 12 m o n t h s ( OS - 1 2 ) a n d 24 m o n t h s ( OS - 2 4 ) vs. Me d i a n O ve r a l l S u r v i val (O S ) r a t e a t 15 m on t h s. C h a r t s h o w s s u r v i val r a t e o f a l l p a t ie n t s in f i r st 24 m on t h s b as e d o n n u m b e r o f t r e a t m e n t cycles. Pa ti e n t s w h o c o m p l e t e d m or e t h an 5 c y c l e s of N E O10 0 tr e a tm e n t d e m onst r a t e d h ig h e r surviv a l r a t e . C h a r t s h o w s s u r v i val r a t e o f p a t ie n t s b a se d o n i nd ica t ion o f I DH1 b i om a rke r in p a t ie n t p r of i le. Stu d i e s d e m o n str a te t h a t p a ti e n t s with I D H 1 do b e tter w it h d isea s e resi s ta n c e . NE O100 O VE RAL L S U RVI V AL R A T E S NE O100 TR E A TM E NT C Y C LE S U RVI V AL R A T E S NE O100 TR E A TM E NT OF P A T E NTS WIT H I D H 1 MARKE R O S 12 M ED IA N 55% OS O S 24 37% C O M P L ET ED L E S S T H A N 5 T R EA T M ENT C Y CLES C O M P L ET ED M O R E T H A N 5 T R EA T M ENT C Y CLES NO I D H 1 M U T A T IO N H A S I D H 1 M U T A T IO NS M on t h s Follo w in g S t a r t o f Tr ea t me n t S ur v i v al % S ur v i v al % S ur v i v al % M on t h s Follo w in g S t a r t o f Tr ea t me n t M on t h s Follo w in g S t a r t o f Tr ea t me n t R e s u l t s D e m o n s t ra t e G r e a t e r S u r v i v a l R a t e s w i t h N E O 100 , P a r t i c u l a r l y f o r P a t i e n t s R e c e i v i n g A dd i t i o na l T r e a t m e n t s C y c l e s an d T h o s e w i t h I D H 1 M a r k e r 20 So u r c e R e por t : N E O 10 0 e n a b l e s b r a i n d e li ve r y of b l oo d - b r a i n b a rr i e r i m p e r me a b l e t h e r a p e u t i cs , S e pt e m b e r 2 , 2020 .

Bef o r e & After N E O 1 0 0 T r eatm e nt B r a i n S c a n S h o w s S i g n i f i c a n t T u m o r R e d u c t i o n a t N i n e M o n t h s F o ll o w i n g T r e a t m e n t w i t h N E O10 0 Octo b er 2023 Jan u ary 2 0 23 21

C o mpa riso n o f Ove r a l l P a t ien t Surv i v a l of Re cur r ent G B M P a t ien t s per T r eat ment M eth o d Sh o wn he r e a r e K a p l a n - M ei er c u rve s r ep r es en t i n g t h e p r obab i l i ty o f surv i va l o f r ec u r r e n t GB M p a t i e n ts un d e r go i n g d i ffe r e n t t r ea t m e n t r egim e n s. N EO 100: P h a s e I s t u dy i n t r a n a s a l t r ea t m e n t r esu l ts ( n = 1 2). Sh o w s h i g h er s u r v i val r a t e w i t h N EO 100 vs. c ur r ent S t a nd a r d o f C a r e. B e va c i zu m a b : si n gle - i n st i t u t i o n r e t r o spec t i ve o f t h e r ea l - wor l d cl i n ica l e x p e rie n c e wi t h ( n = 7 4). Su r g i c a l Resec t i o n : surv i va l r a te for r ec u r r e n t t u mo r s ( n = 4 6), h ist o ric al c o mp a riso n f r o m 1 9 9 8 . L omus t i n e: R a nd o mize d P h a s e III tr i a l whe re p a t i e n ts ( n = 6 5) r ec e i ved Lo m u st i n e o r a l l y ( p u b lis h ed 2 0 1 3 ) . Pe rc e ntag es in t h e c h a r t r efer to O S - 12 a n d 2 - y ea r surv i va l ( O S - 2 4 ) o f t h e d i ffe r e n t t r ea t m e n t r egim e n s a ft e r d i a gn o sis o f r ec u r r e n c e. N E O 100 P h a s e I SURVI V AL vs. Sta n d a r d o f Ca r e M o nth s F o l l o wing S tar t o f T r eatment Ove r a l l S ur v i v al % O S - 12 58% 49% O S - 24 S u r gical Resecti o n 7% 24% 30% N E O100 Phase I Survival Rat e vs. Stand a r d o f Ca r e fo r Recur r ent Hig h - g r ade Glio m as N E O 1 0 0 : 3 7 % 22 IV Beva c iz u m ab 1 5 % Oral L o m u s t i n e < 4%

N E O 10 0 h a s t h e P o t e n t i a l t o O u t p e r f o rm t h e C u rr e nt S t a n d ar d o f C ar e A c r o s s T h e s e K e y T r e a t me n t F a c t o r s What Se t s Us Apart NEO100 vs. C u r r e n t Sta n da r d o f C a r e fo r Rec u r r e n t H i g h - G r ade G l ioma s 1 ) Dru g d o s a g e d o e s n o t r e q u i r e su r g e r y . 2 ) N o sig nifi ca n t sy st e m ic sid e - e ff e ct s r e p o r t e d in o ur N E O 1 0 0 P h a se I clinica l t r i a l . 23 vs. Cu r r ent Sta n d a r d o f Ca r e f o r R e c u r r ent H i g h - G r a d e Gl i omas G li ad el W afers Ga m m a T i les N o vocu r e B e va c izum a b ( A vast in ) O r a l L omu s t ine Repeat S u r g e r y - - ✓ ✓ ✓ - ✓ No S u r ge r y Re qui r ed 1 ✓ ✓ ✓ - - ✓ ✓ B o n e Mar ro w U n a f f ected - - ✓ - - ✓ ✓ N o rma l W o un d Hea l ing ✓ - ✓ ✓ ✓ ✓ ✓ Rad ia t io n N o t R equi r ed ✓ ✓ ✓ - - ✓ ✓ No S y stemi c S id e - e f f e ct s 2 - - - - ✓ - ✓ Easy t o Administ e r T r eatment

NE O 1 0 0 Phase I I Cl i n i ca l T ri a l Underway Pu r p o s e: Det e rmi n e t h e im p a c t o f N E O1 0 0 i n h a lat i o n t h e r a p y o n a s a mp le g r o u p t h a t h a s t h e s a m e c rit eria a s in t h e P h a s e I s t u dy b u t a r e a lso s h o wn to h ave IDH1 mu tat i o n s. In i t i a t ed : C u r r e n t l y e n r o l l i n g T r i a l Si ze: 30 pat i e n ts L oc a t i o n : T a r get 1 2 a ffi n i t y sit e s a c r o ss U . S. P r ot oc o l : Pat i e n ts to be give n 2 8 8 m g o f N E O1 0 0 i n t r a n a s a l l y fo u r t i me s a day ( 1,152 m g t o tal) to d et e rmi n e t h e im p a c t o n t h e i r gl i o m a s. Des i r ed O u t c ome : F r o m t h e data ge n e r a t e d b y t h e tr i a l, we p l a n to seek a p p r o va l f r o m t h e F D A to t r ea t IDH 1 m u ta n t t u mo r s ( G r a de III & G r a de I V ) wi t h N E O1 0 0. Expect P h a s e I I t o p r o v id e th e data ne e ded t o adva n c e N E O100 t o wa r d c o m m er ciali zat i o n . Ph a s e I I C li n i c a l T r i a l Af f i n i t y Si t es Ra t i o n a l e: IDH 1 mu ta n t t u mo r pat i e n ts in t h e tr i a l a r e a t l ea s t t h r ee y ea r s i n to t r ea t m e n t for gl i o m a s — well b e y o n d t h e st u d y ' s b e n c h m a r k o f s ix mo n t h s. ▪ N o ot h er GB M t ri a l h a s h a d t h e sa m e s u rvi val r ate. ▪ C o n sid e ri n g t h e mo d e s t sta nda r ds for GB M dr u g a p p r o va l ( a s e v i d e n c ed b y t h e a p p r o va l o f A va st i n wi t h a 3 - mo n th surv i va l), we a r e h o p ef u l t h e F D A w i l l ap p r o ve N E 0 1 00 for t h e m a rk e t . 24

NE O 2 1 2 Plan n ed Cl i n i ca l T ri a ls Re cei v ed F D A In v estiga t i o na l N e w Dru g (I ND) app r o va l t o in itiate P hase I / I I c l i n i c a l tri a l s of NE O 212 ad m i n i s te r e d o r al l y f o r: ▪ P r i ma r y B r ai n T umo r s. ▪ B r ai n Me t as t asi s in Comb in a t i o n wi th S t an d a r d of Ca r e T h e r a p y . P l a nne d Futu r e T ri a l s t o e v a l ua te NE O212 : ▪ As a s ingl e agent fo r pa t i e nts with p r i ma r y b r ai n tumo r s or unc on t r o l l e d b r ai n m e t a stasi s . ▪ In c o mbina t i o n wit h c o mmon sta nda r d o f ca r e tr eat ments for pati e nts wi th c o l o r e cta l , e s o p ha g e a l , gastri c , k i dn e y , l ung, skin, he a d & ne c k an d oth e r can c e r type s that sp r e a d to the b r ai n . P ha s e I T ri a l E lemen t s: C o mpa riso n of NE O 212 to tem o z o l om i de ( T M Z ) . C an ce r t h e r apeut ic e f f ic a c y in p r eclin ic a l t u mor mo d els: NE O 212 > T M Z (up t o 10x g r eate r ), in cl ud i ng MGM T - p o s i ti v e tumo r s . S y stemi c t o x ic i t y (e.g . , m y elo s upp r es s ion ) NE O212 : < TM Z . P en e t rat i o n o f th e blo o d - b r ai n barrier ( b r ai n se r u m r at i o: N EO21 2 > T M Z ( up to 3x g r e at e r) E x c r eti o n : he patic m e t a b o lis m , no t r e nal . B ioa v a i la bi l i t y : NE O 212 ( 100%) = T M Z ( 100%). Ph a s e I (N o w Underwa y ) M a i n o b j e c ti v e to as s e ss the s a f e ty a n d p r e li m i n a r y e f f i c ac y o f NEO2 12 i n p at e n ts with: ▪ P r i ma r y b r ai n tumo r s ( ca n cer s that sta r t in t he b r ain ) . ▪ B r ai n m e t a stasi s o r i gin at i ng fr om so li d tumo r s that fr e qu e ntly ar i se fr om ca n c e r s of the c o l on , e so ph agus, k i dn e y , l ung an d skin. Ph a s e II Saf e ty & e f f i c ac y o f s i n gl e ag e n t NEO2 12 e v a l u at e d i n p ati e n ts w i th p r i m a r y gl i o m a s a n d m e tastatic br a i n c a n c e r. P h a s e II b Saf e ty & e f f i c ac y o f NEO2 12 e v a l u at e d i n c o m b i n ati on w i th c u r r e n t s tan d a r d - of - c a r e t r e atm e n ts. 25

Pediatric B r ain Can c er P edia tr i c H ig h - G r ade G l iom as (pH G G S) a r e 40 % r e sp on s i ble f or 40% of all c h il d b r ai n tumo r deat hs an d i s the mo s t c o m m on so li d b r ai n tumo r. #1 Th e Need B r ai n T umo r s a r e the L e ad i ng Caus e of Can c e r - Re l at e d Death Amo ng Ch i l d r e n. P r i mar y P ediatric B r ain T umo r s Diagno se d Las t Y e ar 4 , 17 0 Our Solu t ion S o u rce : Na t i o n al B r a i n T u m or S oc i e t y e st i m a t e d f i g u res . C h il d re n = A g e s 0 - 14 26 Th e C h alleng e

Pediat r i c I nd i cat i o n N e x t Steps C a l ifo rni a In sti t u t e f o r Re gene r a t i v e M e dici ne ( C IRM) Appl ic a t i o n • Re c r u i t c l i n i c a l si tes f or stud y to i nc l ud e : • Acq u i r e p r e - c l i n i c a l su p p o r t fr om US C G li om a G r ou p – Gli om a S t e m C e ll s wo r k . • Subm i t C I RM ap p li cat i o n i n J une 2024 on ce pHG S S I ND has b e e n app r o v e d. P edia tr i c Neu r o - onc olog y C o ns o rt i um (PN O C ) E n r o l l ment • IND f i l e d. • App l y f or CI RM g r ant. • Co nd uc t c l i n i c a l tri a l wi th P N O C. R a r e D i s e ase Applicatio n P l a nne d T i m e l i ne • T otal num b e r of pati e nts f or R a r e Dis e as e ap p li c at i on study to be ~40 (Exac t nu mb e r TB D b y IND an d F D A ap p r o val). • Subm i t ap p li c a tio n f or Ra r e Dis e as e sta t us b y Dec e m b e r 2024. • Obtain ap p r o v a l f or Ra r e Dis e as e ap p li cat i on b y Januar y 2025. 27

S pin al C o r d In j u ry B r a i n M et a sta ses Futu r e CN S T r eatment Pos s ibi l ities Pos s i b i l it i e s to E x p lo r e Fol l o w i n g Comm e r cia l Lau n c h of O u r NEO100 & NEO 212 for B r a i n Can cer A l zheime r ' s P ar k i n s o n ' s B y E n a b li n g G r e a t e r P e n e t r a t i o n o f t h e BBB , W e B e li e v e o u r N E O P l a t f o r m C a n T u r n E x i s t i n g F D A - A pp r o v e d D r u g s i n t o M o r e E ff e c t i v e T r e a t m e n t s A c r o s s a F u l l R a n g e o f C N S D i s o r d e r s Au toimm u ne D isease Bi p o l a r D i s o r d e r Mig r a i nes E pil ep s y 28

Futu r e G r o wth Drivers ▪ Comm e r cia l l a unc h of N E O 100 an d N E O 212 f o ll o w i ng F D A ma r ke t ap p r o v a l . ▪ Ad v ancemen t o f NE O100 p e d i at r i c i nd i cat i on . ▪ C l i n i ca l tr i a l s & F D A app r o v al of oth e r P O H - based c o mp o unds in our p r od uct pi pel i n e. ▪ C ur r entl y d e v eloping s e v e r al addi t i o na l p r o prieta r y chem o t h e r a p y agent s that hav e d e m o ns t r at e d p o si tiv e e f f ect s i n l ab o r at o r y tests on oth e r var i ou s type s of ca n c e r s . ▪ T r eat ments f o r o t h er t y pes o f C NS diseases an d diso r ders bas e d on ou r N E O p l at f o rm tec hn o l og y . $ 4 . 2B 202 2 2030 So u r c e : R e s e a r c h a nd M a r k e t s , J u l y 202 2 A l z h e im e r ' s T he r a p eut i c s Mar k et G l o ba l, U SD B illio n s $15.6B 16. 2% C A G R $13.0B 202 1 2028 So u r c e : Zi on M a r k e t R e s e a r c h J u l y 202 2 E p ileps y T he r a p eut i c s Mar k et G l o ba l, U SD B illio n s $ 1 8.1B 3. 5% C A G R $5. 7B 202 1 2031 So u r c e : A lli e d R e s e a r c h , S e pt e m b e r 202 2 Parkinso n ' s Di s ease Dru g Mar k et G l o ba l, U SD B illio n s $10.4B 6. 2% C A G R P o ten t i a l T r eat ments f o r o t h er C NS diseases & D is o rde r s Based on our N E O P latfor m T ec hno l ogy 29

Seni o r Management T eam O u r m a n a geme n t t ea m p o s s ess es sign i fic a n t e x p e rie n c e in c a p i tal m a rk e t s, wi t h a t r a c k r ec o rd o f b u i l d i n g sha r e h o l d er va l u e i n c l i n ica l b i o t e c h c o mp a n i e s. A m i r F . H esh m a t p o ur E xe c u t ive Cha ir m an Tho m as Chen, MD, Ph.D . F o und e r , CE O & CSO P a tric k Wal t ers , CP A Chief O p e r atin g O fficer K eithl y A . G arnett Chief F in an ci a l O fficer 25+ yea r s’ senior e x ec u t iv e & b o a r d e x per ience in busi ness dev el o pm en t , o per a t i o ns, f ina nc e a nd M & A . F o under , c ha ir m a n & m a na ging dir ec t o r o f AFH H o ldi n gs & A dv iso r y, w h e r e he has led IPO t r a nsa c t i o n s t o t a ling $1 billio n + in va lue, a nd pr iv a t e f unding a nd M & A t r a nsa c t i o ns t o t a ling $5 billio n . Prev i o usl y , ser v ed a s c ha ir m a n a nd C E O o f M e t r o ph o ne T elecomm unic a t i o n s , w hic h he f o unded in 199 4. Spear headed gr o w t h f o r o v er a dec a de, lea ding 17 a c quis it i o ns a nd gr o w ing a nnual r ev enu e s t o $10 0+ m illio n . F ounding pa r t ner o f H & H F unding, a pr iv a t e equi t y f ir m in M a libu, C a li fo r nia . H a s c o n t inued t o ser ve o n t he b o a r d o f U C LA A nder son Sch o o l o f M a na gement o v er t he pa st 12 yea r s. U nder gr a d ua t e s tudies, Pe n n S t a t e U niv . B o a r d m ember o f t he M a k e - A - W is h F ounda t i o n f o r C en t r a l C o a st & S o u t her n 30+ yea r s’ m edic a l & c linic a l r esea r c h e x per ience. F o unded a nd o per a t es c linic a l pr a c t ice in b o t h su r gic a l neuro - o nc o l o gy a nd sp ine sur g e r y . H ea ds r esea r c h la b o r a t o r y f o c used o n gli o m a bi o l o gy. B o a r d - c er t i f ied neur osu rge o n a nd dir ec t o r o f Su r gic a l N euro - O n c o l o gy a t U niv . o f S o u t her n C a li fo r nia (US C ). U SC t enur ed Pr o f ess o r o f N eur osu r ge r y & Pa t h o l o gy . 148 + publis hed, peer r ev ie w ed c linic a l s t udies . G r a dua t ed sum m a c um la ude, U niv . o f Illinois a t U r ban a - C ha m p a ig n , wi t h B r o nze T a blet h o n o r s. N eur osu r g e r y t r a i n ing a t U S C . E a r ned Ph.D. in pa t h o bi o l o gy f r o m U S C , f o c used o n t he r o le o f im m un o t her a py in m a lignant br a in t umor s. 30+ yea r s o f e x per ience in f ina nc e , a cc o un ting , a nd o per a t i o ns . P r esident o f G r oup 1 , a dv is ing SM B s in need o f in f r a s t r uc t u r e a nd f ina nc ia l r es t r uc t u r i n g . Prev i o usl y , ser v ed a s E V P F ina nc e f o r M o der n Lu x ur y a nd w a s ins t r umen t a l in inc r easi ng t he va lua t i o n o f t he c o m pany f r o m $54 M t o $23 5M . C lien t s ha ve inc luded a F o r bes 400 f a m ily o ff ic e; a f ina nc ia l ins t it u t i o n; a n e n t er t ainmen t com p any; an d a pro d uc t i o n c o m pa ny. E a r lier ser v ed a s SVP, O per a t i o ns, W o r ld w ide M a r k e t ing f o r S o ny Pic t ur es. B egan c a r eer a t D el o it t e & C o . a s a C P A . C ha ir m a n o f t he b o a r d o f F ir st E n t er t a inm ent C r edit U ni o n w it h a ss e t s o f $1. 2 billio n . 25+ yea r s in c o r p o r a t e f ina nc e, a cc o un ting a nd a dv is o r y ser vic e s. 17 yea r s a t E r nst & Yo ung’s (EY) T r a nsa c t i o n A dv is o r y S e r vic es gr o up. A dv ised For t u n e 500 an d middl e m a r k et c lien t s o n va r i o us t r a nsa c t i o ns f o r f ina nc ia l r ep o r t ing, t a x pla nning a nd s t r a t egic pla nnin g . S e r v ed a s W est R egi o n M a r k e t s F ina nc ia l A dv is o r a t E Y, r esponsi ble f o r lea ding t he f ir m ' s a nnual s t r a t egic a nd f ina nc ia l pla nning pr o c ess a c r o ss se v en indus t r y sec t o r s. E a r lier w o r k ed a t Syc a m o r e V a lua t i o n, a va lua t i o n a nd a cc o un ting a dv is o r y f ir m ser v ing gl o bal c lien t s. Specia lized in va lua t i o n, busi ness m o deling a nd c o r p o r a t e pla nning / s t r a t egy. M B A in C o r p o r a t e F ina nc ia l M a na gement a nd B S in M a na gemen t , U niv er s i t y a t B u f f a l o . C en t r a l V a lley C a li fo r nia . 30

Boa r d o f Di r ectors A m i r F . H esh m a t p o ur E xe c u t ive Cha ir m an Tho m as Chen, MD, PhD F o und e r , CE O & CSO Inde p endent D i r e c t o r N om i n ees Bader A l M o n a w e r D r . V i ctori a M edv e c Richar d Nanula Dr . I ya bo T i nub u - K a r ch 1 M o re t han a decade o f e x perience in ven t ure capi t al, inves t ment ban k ing, and business c o nsul t ing and devel o pmen t . C urren t ly se r ves as managing par t ner o f A rabian Gr o up, o verseeing ven t u r e capi t al inves t men t s. Previ o u s ly f o unded t he VC f und, O asis C api t al, inves t ing in numer o us s t ar t ups, many o f w hich have gr ow n in t o mul t ibillio n - d o ll a r c o rp o ra t i o n s . Ex t e n sive bac k gr o u n d in inves t men t ban k ing and c o nsul t ing at McKi nse y & Compan y, C it ig r o u p ' s M & A a d v is o ry, W afra' s A l t erna t ive Inves t men t s Divisi o n, and t he W o rld Ban k . MB A , Massachu s e tt s Ins t i t u t e o f T echn o l o gy (MI T ); a w arded a merit - based f ell ow ship in rec o gni t i o n o f his o u t s t anding academic e x cellence and pr o f essi o n a l achievemen ts . Mas t er’s degree in ec o n o mics and f inancial p o licy, Co rnell Univer s i t y, w i t h Pi A lpha A lpha h o n o rs. BSc, Indus t rial Engin e eri n g & O pera t i o ns R esearch, Pe n n S t a t e Univers it y. 3 20+ years as C EO o f Medvec & A ss o cia t es, advis o ry f irm se r vicing m o re t han a t hird o f F o r t une 100. A dvising o n reg u la t o ry neg ot ia t i o ns, par t ners h ips and gl o bal mar k et access. C lien t s have included Am gen , San o fi , A s tra Z ene c a , B rist o l My e rs S q uib b , Pfiz e r an d Gi l ea d . F o unding member o f E x t ra o rdinary W o men o n B o ards. Freque n t spea k er and au t h o r o f bes t - selling b ook , " N e go t i a t e Wi th o u t Fea r. A cc o mplished public & priva t e b o ard direc t o r, specializing in mergers and acquisi t i o n s , cus to mer gr ow t h, revenue ma x imiza t i o n, supply chain, human capi t al, and risk managemen t . A pplying e x per t ise in neg ot ia t i o ns and decisi o n - m a k ing t o dri v e reven u e e x pansi o n. Aw a r d - wi nnin g p r o fess o r at N o r t h w es t e r n Univers it y Kell o gg Sch oo l o f Managemen t . R esearch published in t o p j o urnals and highli g h t ed in W SJ, NY T imes, W ashing to n P o s t , T o day S how . Ph.D. Psych o l o gy, Co rnell Univer s i t y. H ighly acc o mplished senior e x ecu t ive and business advis o r w i t h 35+ years’ e x perience in corp o r at e d e vel o pme n t , f inance and M& A . C urren t ly, e x ecu t ive chairman o f Lucy Scien t i f ic, leader psy c h o t r o pi c s - b as e d medicines. Previ o us l y, principal o f Co l o ny C api t al, leading s t ra t egic acquisi t i o n s , including purchase o f First R epublic Bank f o r $1.5B and Miramax Films f o r $650M. E arli e r, served a s E VP o f Financ e & S t r at e g y and C EO o f A mge n , e x ecu t ing acquisi t i o ns t o t aling $18B and implemen t ing f unding ini t ia t ives. A s president & C O O o f S t a r w oo d H o t el s & R es o rt s , spearhead e d in t egra t i o n o f mul t iple c o mpanies, crea t ing wo rld's largest h o spi t ali t y en t erprise valued at $20B. S erved a s EV P & CF O o f W a l t D isn e y Compan y , leading f inancing & t rans fo rma t i ve acquisi t i o ns, and driving revenu e s f r o m $2B t o $20B+ and mar k et cap f r o m $3B t o $40B+. S e rved o n b o ards o f B o eing Co rp o ra t i o n and S t ar woo d Ho t els & R esor t s W o rld w ide. MB A , H arvard Business Sch oo l. 26+ years o f heal t hcare leade rs hip and senior e x ecu t ive e x perience. # 58 F o rbes To p 100 Heal t h c a re Lea d e rs in Middle East 2023. C EO o f Sid ra M e d i c ine , 40 0 - bed wo men’s & children’s h o spi ta l and resear c h cen t er in Q a t ar. F o under & C E O , 6M Geria t ri c s & Ho spi t al Medicine: t eleh e al t h & primary care f o r o ld e r adul t s. C er t i f ied in heal t h I T . Led in t erna t i o nal pr o grams f o r t echn o l o gy in medicine. B o ard app o in t men t s & membe r shi p s at leading c o lleges & socie t ies in U .S.: S w edish Medical C en t er, Dep t . o f Ve t erans Aff airs; VA H eal t hcare Sys t ems, C linical ins t ruc to r a t Univ. o f W a shi n g to n ( U W ) Sch oo l o f Public H eal t h. Mas t ers in H eal t h A dminis t ra t i o n

Sc i ent i f i c Adv i sor y B o a r d O u r Sc i e n t i fic A d v is o r y Boa r d p rov i d e s o b j ec t i ve p e r sp e c t i ve a n d g u i d a n c e in p r o d u c t d e ve l o p m e nt, c l i n ica l tr i a ls, r eg u lat o r y com pl i a n c e, a n d b i o t e c h c o mme r c ial i za t i o n st r a t e gies. Dr . S te v en L G ian n o t t a D r. D an i el Lev i n D r. D a vi d M . Peere b oo m D r. I y a b o Ti nu b u - Karch Axe l H. Sch ö ntha l , P h D Al an C h i ang, M D , P h D . M B A, FICS Ch ai r o f N e u rolo g ica l Su r ge r y a t USC sin c e 1980 . R ese arc h p r i mar ily c e nte r s ar o u n d c e r eb ra l bl oo d fl o w a nd p r o tecting the b ra in f r o m ische m i a . Speciali z es in su r gical st ra tegies f o r c ra ni a l b a se lesi o ns, includi n g a c o ustic neu ro ma s. H a s su r gically r e mo ved 400 + a c o u stic n e ur om a s. Tr e a ted 1,000 + int ra c ra ni a l a neu r ys m s a nd devel o ped a c om p r ehensive a pp ro ac h to c e r eb r o v a scular c o n d iti o ns, e m pl o ying techniq u e s such a s m icr o su r gical clip lig a ti o n, c o il e m b o li za ti o n, a nd ste r e o t a ctic ra di o su r ge r y. M edical deg r ee a nd r esidency a t the Unive r sity o f M ichig a n. 32 F or mer pr e s id e n t o f Nora c Ph a r ma a n d Al kem L ab o r a t o ri es A P I . C u r r ently a p harma c e utical AP I R &D a nd ma n u f a ctu r ing c o ns u lt a nt. E xtensive expe r ience in p harma c e utical p r o c e ss R &D a nd ma n u f a ctu r ing in E u ro pe, Ca n a d a , t h e United St a tes an d I n di a , w o rk i n g with I C I, A st raZ eneca, A vecia, T o r can C he mica l, P i rama l H e a lthc ar e, A lkem L a b o ra t o r ies, a nd N o ra c P h arma . Guided design, devel o pment, ma n u f a ctu r ing, a nd testing o f NeO n c AP I t ar gets. Par t - ti m e c o u n sel o r a nd shift s u pe r vis o r w ith Didi H i r sch M e n t a l H e a lth Se r vic es . M e dica l o n colo g i s t s p e ciali z i n g i n the m a n a g e me n t o f br a i n tum ors , wit h a n ac t i ve pr ac t ic e a t the C l eve l a n d C lin ic . Specialty inte r ests in neu r o - o nc o l o gy a nd expe r i m ent a l the ra peutics . Pr o m inent m e m ber o f the S o ci e ty o f Ne ur o - On c o l o gy. H a s been inv o lved in s om e o f the initi a l o ra l P OH stu d ies. B o ar d c e r tified in Inte r n a l M edicine, a nd in p ra ctice f o r m o r e th a n 2 0 ye ar s. R ec e ived M .D. f r o m Virginia C o mm o n w e a lth Unive r sity Sch oo l o f M edicine. 26 + y e ar s o f he al t h car e l e a d e rsh i p a n d s e n io r exe c ut i ve ex p e ri e n c e. #5 8 F o r bes T o p 10 0 H e a lthc ar e Le a de r s in M iddle Ea st 2023 . CE O o f Sid r a M edicine, 40 0 - bed w o m en ’ s & child r en ’ s h o spit a l a nd r ese arc h c e nter in Q a t ar . F o un der & CEO , 6 M Ge r i a t r ics & Ho spit a l M edicine: telehe a lth & p r i mar y ca r e f o r o lder a d u lts. C e r tified in he a lth I T . Led inte r n a ti o n a l p r o g ram s f o r techn o l o gy in m edicine. B o ar d a pp o int m ents & m e m be r ships a t le a ding c o ll e ges & s o cieties in U.S.: Swedish M edic a l C ente r , D e pt. o f V e te ra ns A ff a i r s; VA H e a lthc ar e Syste m s, C linical inst r uct o r a t Univ. o f W a shing t o n (UW) Sch oo l o f P u b lic H e a lth. M a ste r s in H e a lth A d m inist ra ti o n, Unive r sity o f W a shing t o n. Ass ocia t e P ro f e ss or , De par tmen t o f M o l e c u la r M ic r o bi o l o gy & Imm un o l o gy, Ke c k Sch oo l o f M edicine a t Unive r sity o f S o uthe r n Ca lif o r ni a . R ese arc h f o cused o n n o vel a gents a nd deli v e r y m eth o ds f o r i m p r o ving ca n c e r the ra peutic r egi m ens, p ar ticula r ly f o r b ra in ca n c e r s. A u t h o r ed o r c o au t h o r ed 18 0 sc h o l ar ly ar ticles with a n H - In d ex o f 50 . Over p a st 1 0 ye ar s, engag e d in g ra nt r eviews f o r T h e Q a t a r Na t io n a l R e s e a r c h F und . Includes a pplicati o ns f o r Un d e r g ra d ua te R ese arch E xpe r ience Pr o g ra m th a t engag e s stu d ents in r ese arc h p r o jects u n der the guid a nce o f a ca d e m ic a nd b u siness m ent o r s. P hD, Unive r sity o f K ar ls r u h e, Ge rma ny. P o std o c in m o lecul a r & c e llul a r ca n c e r bi o l o gy a t US C , S a n Dieg o . B oard - c e r t i f i ed neu ro su r ge o n , f o cused o n devel o p m ent o f n o vel p harma c o l o gical a nd inte r venti o n a l t r e a t m ents f o r ca n c e r & C NS dis o r de r s a nd bi o m ech a nic a l stu d ies o n spine su r ge r y. F o u n der & ch a i rma n o f Neu C en B i om edical a nd O r i o n B i o te ch. A ss o ciate Pr o fess o r o f Neu ro su r ge r y a t T a i wa n A dve n tist Ho s p it a l an d Chun g Sh a n Ho spit a l. E xpe r tise in b ra in tu mo r o pe ra ti o n a nd m ini ma lly inv a si v e spine su r ge r y, a nd peer r eviewer f o r seve ra l m edical j o u r n a ls. P u b lished 60 + ar ticles in inte r n a ti o n a l j o u r n a ls. Inte r n a ti o n a l fell o w o f Am e r ican A ss o c. o f Neu ro l o gical Su r ge o ns; m e m ber o f N. Am e r ican Spine S o ci e ty; a nd Inte r n a ti o n a l C o ll e ge o f Su r ge r y Fell o w. P h.D. neu r o - o nc o l o gy, K a o hsiu n g M edical Unive r sity; F r ee Unive r sity o f B e r lin, Ge rma ny. Neu ro su r gical r esidency t ra ining a t Klini k um Steglitz, FU B e r lin. M BA , N a ti o n a l Ta iw a n Unive r sity.

K e y T a k eaways ▪ P r o prieta r y T echn o log y P l a tf o rm ▪ P o t e n t i a l l y n o n - i n va siv e dr u g d e l ivery to t h e b r a i n . ▪ Bi o c o n j u ga t e p l atf o r m f o r n e w c h e m i c a l e n t i t i es. ▪ P a t ented biotech b r ea k t h r o ugh s d e m o ns t r at e d b y num e r ou s p e e r - r e v i e w e d c l i n i c a l stud i e s. ▪ La r ges t U S C I P l i cens e o f biotec h - r ela te d pat ents f or d e v e l o pm e nt & c o mme r c i a l i z a t i o n of ch e mothe r apie s r e l a t ed t o b r ai n & CNS di sea s e s . ▪ First t h r ee t h e r apeut ic d r u g cand i dat es adv an ce d t o P ha s e I & II cl i n i ca l tr i a l s. ▪ Mana gement te a m w i th s i gn i fi ca n t e xp e r i e n c e i n c a p i tal m a r k e ts a n d t r ac k r ec o r d of bu i ldin g sha r eho ld e r val ue in cl in ic a l bi otech c o mpan i e s . ▪ Mult i - bil li o n - d o l la r h i gh g ro wth gl o bal ma r k ets an d g r e a t unm e t m e d i cal ne e d su p p o r t su c c e ss fu l c o m m e r c i a l l aun c h. ▪ $7 5M Nasdaq Gl o bal Mar ke t I P O . 33

T H E F U T U R E O F D R U G D E L I V E R Y Company Co n tact N eO n c T ec hn o l o gies Ho l d i n gs , I n c . T wo Do le Drive W est l a k e V i l lag e, CA 9 1 3 6 2 T el +1 ( 3 1 0) 6 6 3 - 7831 I n f o @ n e o n c t ec h . c o m ww w . n e o n t e c h . c o m M e dia C o n t act T i m R a n dall C M A M e d i a Relati o n s N eO n c @c m a . t e a m T el +1 ( 9 4 9) 4 7 2 - 7566 In v est o r C o n t act Ro n Bo t h o r G r a n t S t u de C M A I n vest o r Relati o n s N eO n c @c m a . t e a m T el +1 ( 9 4 9) 4 7 2 - 7566 Cont a c t Us 34